PMID- 8561906
OWN - NLM
STAT- MEDLINE
DCOM- 19960305
LR  - 20190825
IS  - 0166-4328 (Print)
IS  - 0166-4328 (Linking)
VI  - 70
IP  - 2
DP  - 1995 Oct
TI  - Kainic acid decreases hippocampal neuronal number and increases dopamine receptor 
      binding in the nucleus accumbens: an animal model of schizophrenia.
PG  - 153-64
AB  - Intracerebroventricular (i.c.v.) administration of kainic acid (KA) produces 
      graded neuronal loss in the hippocampus and other regions of the medial temporal 
      lobe. Many of these brain regions send excitatory projections to the nucleus 
      accumbens, a dopaminergic brain area implicated in psychotomimetic and 
      antipsychotic drug action. In the present study, neurochemical function in the 
      nucleus accumbens and anterior caudate-putamen was examined one week after i.c.v. 
      administration of 1.5, 4.5, or 6.6 nmol of KA. As expected, i.c.v. KA produced 
      dose-dependent neuronal loss in the dorsal and ventral hippocampus. 
      Extrahippocampal neuronal loss was also observed in the thalamus and piriform 
      cortex in some of the KA-treated rats. While ambient levels of dopamine turnover 
      and excitatory amino acids in the nucleus accumbens were unaltered by KA, 
      administration of the highest KA dose elevated [3H]spiperone binding exclusively 
      in the accumbens. Finally, behavioral hyperactivity was observed in KA-treated 
      rats over a five-week period following i.c.v. administration. The pattern of 
      neuronal loss, receptor upregulation, and behavioral hyperactivity found after 
      i.c.v. KA administration may provide a useful animal model of the limbic 
      neuropathology and neurochemical dysfunction associated with schizophrenia.
FAU - Bardgett, M E
AU  - Bardgett ME
AD  - Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 
      63110-1093, USA.
FAU - Jackson, J L
AU  - Jackson JL
FAU - Taylor, G T
AU  - Taylor GT
FAU - Csernansky, J G
AU  - Csernansky JG
LA  - eng
GR  - AA07144/AA/NIAAA NIH HHS/United States
GR  - MH01109/MH/NIMH NIH HHS/United States
GR  - MH14677/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Behav Brain Res
JT  - Behavioural brain research
JID - 8004872
RN  - 0 (Receptors, Dopamine)
RN  - 4X6E73CJ0Q (Spiperone)
RN  - SIV03811UC (Kainic Acid)
SB  - IM
MH  - Animals
MH  - Brain Mapping
MH  - Caudate Nucleus/drug effects/physiopathology
MH  - Cell Count/drug effects
MH  - *Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Hippocampus/*drug effects/physiopathology
MH  - Injections, Intraventricular
MH  - Kainic Acid/*pharmacology
MH  - Male
MH  - Motor Activity/drug effects/physiology
MH  - Nerve Degeneration/drug effects/physiology
MH  - Neural Pathways/drug effects/physiopathology
MH  - Nucleus Accumbens/*drug effects/physiopathology
MH  - Putamen/drug effects/physiopathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Dopamine/*drug effects/physiology
MH  - Schizophrenia/*chemically induced/physiopathology
MH  - Spiperone/pharmacokinetics
MH  - Temporal Lobe/drug effects/physiopathology
MH  - Up-Regulation/drug effects/physiology
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 0166-4328(95)80005-0 [pii]
AID - 10.1016/0166-4328(95)80005-0 [doi]
PST - ppublish
SO  - Behav Brain Res. 1995 Oct;70(2):153-64. doi: 10.1016/0166-4328(95)80005-0.